Aduro Biotech, Inc. (ADRO): Thomas W. Dubensky , Chief Scientific Officer of Aduro Biotech, Inc. sold 25,000 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 7, 2016 to the Securities and Exchange Commission. The shares were sold at $11.61 per share for a total value of $290,250.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Dirk G. Brockstedt (Sr. VP of Research and Dev.) sold 905 shares at $8.20 per share price.On May 18, 2016, Gregory W Schafer (Chief Operating Officer) sold 905 shares at $8.20 per share price.Also, On May 18, 2016, Thomas W. Dubensky (Chief Scientific Officer) sold 905 shares at $8.20 per share price.On Jan 6, 2016, Stephen T Isaacs (President and CEO) sold 25,000 shares at $26.63 per share price.
Shares of Aduro BioTech Inc (ADRO) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.33 points or -2.70% at $11.91 with 4,22,283 shares getting traded. Post opening the session at $11.61, the shares hit an intraday low of $11.5 and an intraday high of $12.15 and the price vacillated in this range throughout the day. The company has a market cap of $770 M and the number of outstanding shares has been calculated to be 6,46,11,916 shares. The 52-week high of Aduro BioTech Inc is $34.95 and the 52-week low is $7.26.
Company has been under the radar of several Street Analysts.Aduro BioTech Inc is Reiterated by FBR Capital to Outperform while Lowering the Price Target of the company shares to $ 22 from a previous price target of $30 . The Rating was issued on May 17, 2016.
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live attenuated Listeria GVAX and cyclic dinucleotides (CDNs). Aduros lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207 ADU-623 ADU-214 ADU-741 CDN and STINGVAX. CRS-207 is based on Aduros Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.